When should ApoB be retested?

The optimal timing for retesting ApoB depends on individual cardiovascular risk and treatment status. ApoB (apolipoprotein B) directly reflects the number of atherogenic particles and is a more accurate risk marker than LDL cholesterol alone. For primary prevention in low-risk adults, guidelines (e.g., ESC/EAS) recommend lipid screening every 4–6 years. For high-risk individuals (diabetes, familial hypercholesterolemia, established atherosclerosis) or those on lipid-lowering therapy (statins, PCSK9 inhibitors), shorter intervals are warranted – typically every 3–12 months until target levels are achieved. After therapy adjustment, retest ApoB after 4–12 weeks. Importantly, a single value is a snapshot; trends over time matter most. Evidence is strong (human-strong) from large cohorts and RCTs confirming ApoB's predictive superiority. However, retesting decisions should be made with a physician who considers overall risk. MyBody-X tests provide reliable lab results but do not replace clinical diagnosis. Abnormal results require medical follow-up.